Prevention of heterotopic ossification with localized delivery of arsenic trioxide loaded nanoparticles as a novel treatment for fibrodysplasia ossificans progressiva - fibrodysplasia ossificans…
Active Project Grant Awarded Last action
- Award ID
- R21TR005159
- Recipient
-
Nostopharma LLC UEI FKVPNPQK64H8
- Awarding agency
-
National Center for Advancing Translational Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $407,792
Award facts
- Assistance listing
- 93.350 National Center for Advancing Translational Sciences
- Completion date 69% complete
- Place of performance
- Washington, DC, USA
Award details come from USAspending.gov.
Description
Prevention of heterotopic ossification with localized delivery of arsenic trioxide loaded nanoparticles as a novel treatment for fibrodysplasia ossificans progressiva - fibrodysplasia ossificans progressiva (FOP) is an ultrarare genetic disease that affects around 1 in 1.5-2.0 million live births, in which a point mutation in ACVR1, encoding the type 1 abnormal bone morphogenetic protein (BMP) receptor ALK2, causes aberrant BMP signaling. The aberrant signaling leads to a rapid and progressive endochondral heterotopic ossification (EHO) in skeletal muscle and connective tissues as a hallmark of the FOP. All of FOP preventative drugs have a systemic application and are used chronically to lessen the risk of flare-UPS and/or the development of new EHO. Therefore, there are no treatments for FOP under clinical development that are acutely acting and/or supplied locally. Nostopharma seeks to address this need by creating locally administered, small volume, extended-release formulations of hedgehog pathway (HH) inhibitors as a promising approach to achieve a therapeutic effect, dose, and toxicity reduction. The objective for this preclinical proof of concept is to demonstrate the feasibility of eliminating systemic drug exposure and repurposing of clinically tested and previously authorized inhibitors of endochondral bone formation, such as HH signaling inhibitors, formulated in a proprietary way, to treat a rare genetic disease-FOP. Hedgehog signaling (HH) has a seminal role in mesenchymal progenitor fate choice and inappropriate differentiation into osteoblasts and ectopic bone formation in soft tissues. Although arsenic trioxide (ATO), a highly potent HH inhibitor, can directly block osteogenesis, chronic or systemic delivery is not an option for FOP patients due to recognized side effects in tissues that are not the intended target. To circumvent these restricting side effects, a proprietary formulation of ATO encapsulated in immunomodulatory nanoparticles was developed. This proof of concept will involve screening of dose and frequency of intramuscular administration required to significantly reduce intramuscular EHO in an AVCR1R206H expressing mouse model of FOP.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $407,792 |
Quick answers
Who received award R21TR005159?
R21TR005159 was awarded to Nostopharma LLC by National Center for Advancing Translational Sciences (National Institutes of Health) on July 3, 2025.
How much is award R21TR005159 worth?
$407,792 has been obligated on R21TR005159.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award